Earnings summaries and quarterly performance for iRhythm Technologies.
Executive leadership at iRhythm Technologies.
Quentin Blackford
Detailed
President and Chief Executive Officer
CEO
CP
Chad Patterson
Detailed
Chief Commercial Officer
DW
Daniel Wilson
Detailed
Chief Financial Officer
MS
Mervin Smith
Detailed
Executive Vice President, Business Operations
MT
Mintu Turakhia
Detailed
Chief Medical Officer, Chief Scientific Officer, and EVP, Product Innovation
PM
Patrick Murphy
Detailed
Chief Business Officer and Chief Legal Officer
SS
Sumi Shrishrimal
Detailed
Executive Vice President, Chief Risk Officer
Board of directors at iRhythm Technologies.
Research analysts who have asked questions during iRhythm Technologies earnings calls.
DR
David Rescott
Baird
4 questions for IRTC
Also covers: HAE, INSP, LIVN +7 more
SK
Suraj Kalia
Oppenheimer & Co. Inc.
4 questions for IRTC
Also covers: ABT, AORT, ATRC +14 more
AG
Allen Gong
JPMorgan Chase & Co.
3 questions for IRTC
Also covers: ESTA, GKOS, INGN +2 more
DR
David Roman
Goldman Sachs Group Inc.
3 questions for IRTC
Also covers: ABT, BAX, BDX +18 more
Kallum Titchmarsh
Morgan Stanley
3 questions for IRTC
Also covers: ATEC, AXNX, EMBC +5 more
MK
Macauley Kilbane
William Blair & Company
3 questions for IRTC
Also covers: CBLL, CVRX, GKOS +4 more
NT
Nathan Treybeck
Wells Fargo Securities
3 questions for IRTC
Also covers: ITGR, LMAT, NVRO +1 more
RN
Richard Newitter
Truist Securities
3 questions for IRTC
Also covers: AXNX, DXCM, GKOS +18 more
DS
David Saxon
Needham & Company
2 questions for IRTC
Also covers: ALC, ALGN, ATEC +11 more
JY
John Young
Canaccord Genuity - Global Capital Markets
2 questions for IRTC
Also covers: ANGO, CVRX, LUNG +2 more
Marie Thibault
BTIG
2 questions for IRTC
Also covers: ABT, ARAY, ATRC +15 more
Anthony Occhiogrosso
Citigroup Inc.
1 question for IRTC
Also covers: HAE
Bill Plovanic
Canaccord Genuity
1 question for IRTC
Also covers: AORT, CBLL, DXCM +6 more
BV
Brandon Vazquez
William Blair & Company, L.L.C.
1 question for IRTC
Also covers: ALGN, CBLL, CVRX +16 more
LL
Lilia-Celine Lozada
JPMorgan Chase & Co.
1 question for IRTC
Also covers: ATRC, BVS, CBLL +4 more
PB
Philippe Belamant
Truist Securities
1 question for IRTC
Sam Eiber
BTIG, LLC
1 question for IRTC
Also covers: AIRS, APYX, EMBC +6 more
William Plovanic
Canaccord Genuity
1 question for IRTC
Also covers: ATRC, CBLL, CVRX +9 more
Recent press releases and 8-K filings for IRTC.
iRhythm Technologies Discusses 2025 Performance, 2026 Outlook, and Product Pipeline
IRTC
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- iRhythm (IRTC) maintains a strong market position with over 70% share in long-term continuous monitoring (LTCM) and approximately 15% share in mobile cardiac telemetry (MCT).
- The company expects an 8% increase in Medicare rates for LTCM in 2026, which represents 25% of its revenue, with commercial rates anticipated to remain stable.
- Revenue acceleration in 2025 was driven by strong Zio AT performance, growth in the Innovative Channel, and core Zio Monitor business acceleration, with over 50% of volume now processed through EHR integrations, yielding a consistent 25% uplift in integrated accounts.
- iRhythm submitted a 510(k) for its next-generation Zio MCT device in early September, which will offer 21 days of wear, though it is not expected to meaningfully impact 2026 revenue and is projected as a 2027 driver.
- For fiscal year 2026, the company anticipates revenue growth of 16%-18% and expects to be free cash flow positive for the first time in 2025, targeting 15% adjusted EBITDA by 2027.
Dec 4, 2025, 2:10 PM
iRhythm Technologies Reviews Strong 2025 Performance and Provides 2026 Outlook
IRTC
Revenue Acceleration/Inflection
Guidance Update
Product Launch
- iRhythm Technologies reported a "phenomenal year" in 2025 with accelerated revenues, attributing growth to strong Zio AT performance, expansion in the innovative channel, and core Zio Monitor business acceleration through EHR integration and primary care penetration.
- The company provided a preliminary 2026 revenue growth outlook of 16% to 18%, noting this reflects difficult comparable periods following 2025's acceleration.
- The next-generation mobile cardiac telemetry (MCT) product, Zio MCT, submitted for 510(k) FDA clearance in early September, is expected to be a 2027 driver rather than a meaningful contributor to 2026 revenue.
- For 2026, Medicare rates for long-term continuous monitoring (LTCM) are expected to increase by 8%, though Medicare accounts for only 25% of the company's revenue.
- iRhythm achieved free cash flow positive status for the first time in 2025 and is on track for a 15% adjusted EBITDA target by 2027.
Dec 4, 2025, 2:10 PM
iRhythm Discusses 2025 Performance, 2026 Outlook, and Product Development
IRTC
Revenue Acceleration/Inflection
Guidance Update
Product Launch
- iRhythm reported a "phenomenal year" in 2025 with revenue acceleration, driven by strength in its Zio AT product, competitive disruption, growth in the Innovative Channel, and increased EHR integration.
- For 2026, Medicare rates for Long-Term Continuous Monitoring (LTCM) are expected to increase by 8%, while Mobile Cardiac Telemetry (MCT) rates are projected to slightly decrease.
- The company provided a preliminary outlook for 16%-18% growth in 2026, acknowledging difficult comparisons from 2025.
- iRhythm submitted its next-generation Zio MCT device to the FDA via a 510(k) in early September 2025, but it is not expected to meaningfully contribute to 2026 revenue.
- iRhythm anticipates being free cash flow positive for the first time in 2025 and is on pace to achieve a 15% adjusted EBITDA target in 2027.
Dec 4, 2025, 2:10 PM
iRhythm Discusses Market Growth, Product Pipeline, and 2026 Outlook
IRTC
Guidance Update
Product Launch
New Projects/Investments
- iRhythm's CFO, Dan Wilson, highlighted the company's transition to a profitable growth company. The long-term continuous monitoring market, where iRhythm holds a low 70% share, is growing at high teens % year over year, with iRhythm gaining 1-2 points of market share.
- Key growth drivers include the increasing adoption in primary care, which now accounts for 30% of Zio XT patch usage, up from 20%. The company also benefits from the Pulsed Field Ablation trend and over 50% of its volume coming through EHR integration.
- The Zio MCT product was submitted to the FDA in early September but is not expected to contribute to 2026 revenue. Positively, Medicare rates for Zio Monitor are increasing by approximately 8% for next year, impacting 25% of the company's revenue.
- iRhythm has expanded its international presence, launching in five new markets in the last 12-14 months, with significant contributions anticipated from 2027 and beyond. The company is also investing in a multi-vitals platform for future opportunities such as sleep apnea.
- For 2026, iRhythm is comfortable with preliminary revenue guidance in the 16%-18% range, emphasizing a "thoughtful" approach to guidance and a commitment to 400 basis points of adjusted EBITDA expansion year to year.
Dec 3, 2025, 6:00 PM
iRhythm Technologies Discusses 2026 Outlook and Strategic Initiatives
IRTC
Guidance Update
Product Launch
New Projects/Investments
- iRhythm Technologies provided preliminary 2026 revenue guidance, indicating comfort with street numbers in the 16%-18% growth range, with less predictable areas like the Innovative Channel considered potential upside.
- The company continues to lead the long-term continuous monitoring market, which is growing at high teens percent year-over-year, and is gaining 1-2 points of market share. A significant driver is the shift to primary care, now accounting for 30% of Zio XT patch usage.
- Zio MCT was submitted to the FDA in early September 2025, but is not expected to contribute to 2026 revenue. Medicare rates for long-term continuous monitoring (Zio Monitor) are projected to increase by approximately 8% in 2026.
- iRhythm is expanding internationally into five new markets and investing in a multi-vitals platform for future opportunities, particularly in sleep apnea, though these are mid to longer-term drivers.
Dec 3, 2025, 6:00 PM
iRhythm Technologies Reports Strong Q3 2025 Results and Updates Full-Year Guidance
IRTC
Earnings
Guidance Update
New Projects/Investments
- iRhythm Technologies reported Q3 2025 revenue of $192.9 million, a 30.7% year-over-year increase, with a gross margin of 71.1% and adjusted EBITDA margin of 11.2%.
- The company updated its full-year 2025 revenue guidance to $735 million to $740 million, representing 24-25% year-over-year growth, and expects adjusted EBITDA margin between 8.25-8.75%.
- iRhythm is guiding to be free cash flow positive for the full year 2025, marking a significant milestone for the company.
- The company identifies substantial market expansion opportunities, including 27 million patients for Zio monitoring in the U.S. and 5 million tests in prioritized international countries, supported by new product development like Zio MCT and a future multivitals platform.
- Strategic growth initiatives include expanding into primary care, leveraging EHR integration for over 50% of its volume, and partnerships such as with Lusum Health for proactive population health management.
Nov 20, 2025, 10:00 AM
iRhythm Technologies Reports Strong Q3 2025 Results and Raises Full-Year Guidance
IRTC
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- iRhythm Technologies reported Q3 revenue of $192.9 million, marking 30.7% year-over-year growth, and updated its full-year 2025 revenue guidance to between $735 million and $740 million, representing 24-25% year-over-year growth.
- The company achieved a gross margin of 71.1% and an adjusted EBITDA margin of 11.2% in Q3, with full-year 2025 adjusted EBITDA margin guidance of 8.25% to 8.75%. Notably, iRhythm expects to be free cash flow positive for the full year 2025, a significant first for the company.
- iRhythm is pursuing a substantial market opportunity, identifying 27 million patients as candidates for Zio monitoring, and is expanding its reach through international markets and by moving upstream into primary care.
- The company is advancing its product pipeline with the next-generation Zio MCT and developing a multivitals platform for deeper insights and new market opportunities, while leveraging EHR integration (over 50% of volume) for operational efficiency and sticky customer relationships.
Nov 20, 2025, 10:00 AM
iRhythm Technologies Reports Strong Q3 2025 Results and Updates Full-Year Guidance
IRTC
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- iRhythm Technologies reported Q3 2025 revenue of $192.9 million, demonstrating 30.7% year-over-year growth.
- The company updated its full-year 2025 revenue guidance to between $735 million and $740 million, representing 24-25% year-over-year growth, and expects adjusted EBITDA margin between 8.25-8.75%.
- iRhythm anticipates being free cash flow positive for the full year 2025, a significant milestone in the company's history.
- The company is actively pursuing market expansion opportunities, including a 27 million patient total addressable market (TAM) for ambulatory cardiac monitoring, international markets, and increased penetration into primary care.
- iRhythm is developing new products such as Zio MCT (recently submitted to the FDA) and a multivitals platform to gather more patient data and explore adjacent markets like sleep.
Nov 20, 2025, 10:00 AM
iRhythm Technologies Discusses Regulatory Landscape, Strong 2025 Performance, and 2026 Outlook
IRTC
Guidance Update
Product Launch
New Projects/Investments
- iRhythm's CFO addressed concerns regarding a draft Local Coverage Decision (LCD) by three Medicare Administrative Contractors (MACs) for ambulatory cardiac monitoring, expressing confidence the process will resolve favorably and that the MACs did not intend to apply Mobile Cardiac Telemetry (MCT) guidelines to all modalities.
- The company's current 2025 revenue guidance is 8% higher than the original midpoint, driven by strong performance in XT monitor, AT, and Innovative Channel Partners (ICPs). Q4 2025 guidance implies a 21% year-on-year growth at the midpoint, a deceleration from Q3's 31%, attributed to a difficult comparable quarter in Q4 last year.
- For 2026, iRhythm is comfortable with Street's model of high-teens revenue growth, which excludes any contribution from the next-gen MCT device.
- A 510(k) submission for the next-gen MCT device was made in September , with a full commercial launch anticipated for the second half of 2026. This new device will offer 21 days of continuous monitoring, an increase from AT's 14 days.
- Innovative Channel Partners (ICPs) now total 18 and contributed low single digits to total revenue in Q2 and Q3 2025.
Nov 18, 2025, 2:20 PM
iRhythm Technologies Discusses Strong 2025 Performance, 2026 Outlook, and Regulatory Updates
IRTC
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- iRhythm Technologies (IRTC) addressed concerns regarding a draft Local Coverage Decision (LCD) by three Medicare Administrative Contractors (MACs) for ambulatory cardiac monitoring, expressing confidence that the process will result in a favorable outcome.
- The company's 2025 revenue guidance is 8% higher than its original midpoint, driven by strong performance in its XT monitor, AT product, and Innovative Channel Partners (ICPs).
- For 2026, iRhythm anticipates high-teens revenue growth, excluding any contribution from its next-gen Mobile Cardiac Telemetry (MCT) device, which was submitted for 510(k) clearance in September and is expected to launch in the second half of 2026.
- Innovative Channel Partners (ICPs) contributed a low single-digit percentage of total revenue in Q2 and Q3 2025, with management noting that every partner that has completed a pilot has continued to a full commercial program.
- iRhythm has fully executed its FDA remediation plan and is undergoing an independent third-party audit of its quality management system, with results to be provided to the FDA.
Nov 18, 2025, 2:20 PM
Quarterly earnings call transcripts for iRhythm Technologies.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more